{"product_id":"zhifeishengwu-business-model-canvas","title":"Chongqing Zhifei Biological Products Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChongqing Zhifei: Concise Business Model Canvas for Investors \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Chongqing Zhifei Biological Products's business model—this concise Business Model Canvas dissects value propositions, key partnerships, revenue streams, and scalability levers to show how the company captures market share in biopharma; ideal for investors, consultants, and founders seeking actionable, ready-to-use insights—download the complete Word\/Excel canvas to benchmark, plan, or present with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Merck Sharp and Dohme\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe exclusive distribution deal with Merck Sharp \u0026amp; Dohme (MSD) runs through late 2025 and anchors Zhifei’s sales strategy, giving Zhifei China rights to Gardasil HPV (annual demand \u0026gt;20m doses in 2024) and MSD’s 23-valent pneumococcal vaccine; these products contributed an estimated RMB 3.1bn to Zhifei revenue in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration with Local Centers for Disease Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZhifei partners with provincial and municipal Centers for Disease Control across China, which account for over 85% of its vaccine procurement and serve as primary buyers and regulators of immunization programs. The company aligns supply with regional immunization schedules and public-health priorities—helping fulfill government tenders that generated RMB 4.2 billion (2024 sales tied to CDC channels) and support timely delivery to meet scheduled campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Research with Academic and Scientific Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChongqing Zhifei Biological Products partners with top Chinese universities (e.g., Tsinghua, Sichuan Univ.) and institutes to co-develop recombinant-protein and mRNA vaccine platforms, cutting R\u0026amp;D time by ~20% and lowering preclinical costs; joint projects accounted for ~15% of Zhifei’s R\u0026amp;D spend (RMB 220m of RMB 1.45bn) in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZhifei maintains a strong network of specialized suppliers for biological reagents and manufacturing equipment, securing multi-year contracts to stabilize supply and cap price volatility—critical after 2023 reagent shortages that pushed input costs up ~12% in China’s vaccine sector.\u003c\/p\u003e\n\u003cp\u003eThese partnerships ensure consistent high-quality inputs so Zhifei meets China NMPA (National Medical Products Administration) GMP standards and sustained output for vaccines like the 2020–25 pediatric portfolio.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eMulti-year contracts reduce price swings\u003c\/li\u003e\n\u003cli\u003eSupplier audits ensure NMPA GMP compliance\u003c\/li\u003e\n\u003cli\u003eMitigates past 12% reagent-cost shock\u003c\/li\u003e\n\u003cli\u003eSupports continuous production for pediatric vaccines\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing with International Biotech Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZhifei signs licensing and co-development deals with international biotech firms to add shingles and RSV vaccines to its portfolio, shifting away from sole reliance on MSD products and targeting higher-margin preventive medicines; by 2025 these partnerships aim to capture China’s aging and pediatric markets where specialized vaccine ASPs exceed commodity vaccines by 2–4x. \u003c\/p\u003e\n\u003cp\u003eThese agreements often include technology transfer and local clinical programs that upgraded Zhifei’s biologics manufacturing, with reported R\u0026amp;D collaboration deals totaling \u0026gt;CNY 1.2 billion in 2024–25 and expected to boost vaccine margin contribution by ~6–10 percentage points. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdds shingles, RSV via licensing\u003c\/li\u003e\n\u003cli\u003eTech transfer + co-dev phases\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D deals \u0026gt; CNY 1.2B (2024–25)\u003c\/li\u003e\n\u003cli\u003eTarget: 2–4x higher ASPs, +6–10pp margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong partner mix fuels RMB growth: MSD deal, CDC demand, R\u0026amp;D \u0026amp; licensing upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners: MSD exclusive China deal (Gardasil, 23-valent; ~RMB 3.1bn revenue 2024, runs to late 2025), CDCs (85% procurement, RMB 4.2bn 2024), top universities (co-dev = RMB 220m R\u0026amp;D 2024, ~20% faster R\u0026amp;D), suppliers (multi-year contracts, mitigated 12% reagent shock), intl licensing (R\u0026amp;D deals \u0026gt;CNY 1.2bn 2024–25, target +6–10pp margins).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSD\u003c\/td\u003e\n\u003ctd\u003eExclusive distributor\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1bn (2024); contract→late 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDCs (prov.\/mun.)\u003c\/td\u003e\n\u003ctd\u003ePrimary buyers\u003c\/td\u003e\n\u003ctd\u003e85% procurement; RMB 4.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnivs\/Inst.\u003c\/td\u003e\n\u003ctd\u003eCo‑development\u003c\/td\u003e\n\u003ctd\u003eRMB 220m R\u0026amp;D (2024); −20% dev time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eInput stability\u003c\/td\u003e\n\u003ctd\u003eMitigated 12% reagent cost shock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl biotech\u003c\/td\u003e\n\u003ctd\u003eLicensing\/tech transfer\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;CNY 1.2bn deals (2024–25); +6–10pp margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Chongqing Zhifei Biological Products, detailing customer segments, value propositions, channels, revenue streams, key activities, resources, partners, cost structure, and risk factors aligned with its vaccine and biologics operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Chongqing Zhifei Biological Products’ business model with editable cells, helping teams quickly pinpoint vaccine development, manufacturing, distribution, and regulatory touchpoints to streamline strategy and collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZhifei spends ~RMB 1.2bn on R\u0026amp;D in 2024 (11% of revenue), running multi‑phase clinical programs at three R\u0026amp;D centers to win approvals for self‑developed meningococcal and TB vaccines; these trials carry typical Phase II–III costs of tens‑to‑hundreds of millions and are key to shifting from distribution to higher‑margin, proprietary biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Scale Vaccine Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChongqing Zhifei Biological operates state-of-the-art GMP facilities that in 2024 produced over 300 million vaccine doses annually, handling pathogen cultivation, multi-stage purification, and large-scale formulation to meet China’s immunization needs. Maintaining \u0026gt;95% batch yield and ISO-aligned quality controls reduces cost per dose and ensures public safety, with R\u0026amp;D and manufacturing capex of about CNY 1.2 billion in 2023 supporting scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Promotion and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei deploys a \u0026gt;4,000-strong sales and medical affairs team to run academic seminars, present at \u0026gt;200 domestic and international conferences annually, and deliver community outreach reaching ~1.2 million people in 2024; these activities lifted vaccine uptake and helped drive 2024 vaccine revenue to RMB 8.1 billion, accelerating adoption of both distributed and proprietary products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold Chain Logistics and Distribution Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging a sophisticated cold chain is a core activity that preserves vaccine potency from factory to injection; Zhifei operates nationwide refrigerated hubs and over 1,200 refrigerated vehicles as of 2025, maintaining 2–8°C or -20°C where required to meet regulatory standards.\u003c\/p\u003e\n\u003cp\u003eThis logistics network lets Zhifei serve remote western provinces, supporting annual distribution volumes exceeding 200 million doses in 2024 and reducing cold-chain loss rates below 0.5%, a clear competitive edge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,200+ refrigerated vehicles (2025)\u003c\/li\u003e\n\u003cli\u003e200M+ doses distributed (2024)\u003c\/li\u003e\n\u003cli\u003eTemperature ranges: 2–8°C and -20°C\u003c\/li\u003e\n\u003cli\u003eCold-chain loss \u0026lt;0.5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZhifei’s compliance teams continuously monitor China’s National Medical Products Administration rules and run batch-level quality checks; in 2024 their QC labs tested \u0026gt;1.2 million vials, supporting a 99.6% batch-release pass rate that preserves licenses and trust.\u003c\/p\u003e\n\u003cp\u003eThey also audit marketing and KOL engagements to meet national advertising and anti-bribery rules, preventing fines that could exceed CN¥50M and safeguarding relationships with provincial CDCs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;1.2M vials QC tested in 2024\u003c\/li\u003e\n\u003cli\u003e99.6% batch-release pass rate\u003c\/li\u003e\n\u003cli\u003eCompliance prevents fines \u0026gt;CN¥50M\u003c\/li\u003e\n\u003cli\u003eMaintains licensure and government trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhifei: RMB1.2bn R\u0026amp;D, 300M+ doses\/yr, 99.6% batch pass, 200M+ distributed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei runs 3 R\u0026amp;D centers, spent ~RMB 1.2bn on R\u0026amp;D (11% of revenue) in 2024, and operates GMP plants producing 300M+ doses annually with \u0026gt;95% batch yield, supporting distribution of 200M+ doses (2024) via 1,200+ refrigerated vehicles (2025) and QC testing \u0026gt;1.2M vials with 99.6% batch‑release pass rate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn (11% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction\u003c\/td\u003e\n\u003ctd\u003e300M+ doses\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributed\u003c\/td\u003e\n\u003ctd\u003e200M+ doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain fleet\u003c\/td\u003e\n\u003ctd\u003e1,200+ vehicles (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQC tested\u003c\/td\u003e\n\u003ctd\u003e1.2M+ vials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch pass rate\u003c\/td\u003e\n\u003ctd\u003e99.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Chongqing Zhifei Biological Products Business Model Canvas shown here is the actual deliverable, not a mockup or sample; it’s a direct snapshot of the exact file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order, you’ll download this same professional, ready-to-edit document—formatted and structured exactly as previewed, with all content included.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749691076985,"sku":"zhifeishengwu-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zhifeishengwu-business-model-canvas.png?v=1772217119","url":"https:\/\/matrixbcg.com\/products\/zhifeishengwu-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}